PRESS RELEASES NEWS MEDIA GALLERY MEDIA CONTACTS

NOTICE TO OSLO BØRS – LAST DAY OF TRADING, EXPIRED CREDITOR NOTICE PERIOD, SCHEDULE FOR COMPLETION ETC. (15.01.13)

Reference is made to stock exchange notices of 12 September, 8 October and 9 November 2012 regarding the merger between Aker BioMarine ASA ("AKBM") as transferor company, and Aker Seafoods Holding AS ("AKSH") as transferee company, with consideration shares in AKSH‘s parent company Aker ASA ("AKER").

NOTICE TO OSLO BØRS –SCHEDULE FOR COMPLETION OF MERGER (14.01.13)

Mandatory notification of trade (12.11.12)

Aker Seafoods Holding AS, a wholly owned subsidiary of Aker ASA, a company controlled by Kjell Inge Røkke, the chairman of the board in Aker BioMarine ASA, has on 12 November 2012 purchased 36 527 419 shares in Aker BioMarine ASA to a price per share of NOK 1.32.

As a result of the purchase, Aker Seafoods Holding AS owns 1 046 658 324 shares in Aker BioMarine ASA, corresponding to 89.2 per cent of the outstanding shares and votes in the company.

Concequently, Røkke controls, directly and indirectly, 1 046 658 324 shares in Aker BioMarine ASA, corresponding to 89.2 per cent of the outstanding shares and votes in the company.

Merger approved – Minutes from the extraordinary general meeting (09.11.12)

Reference is made to stock exchange notices of 12 September, 19 September and 8 October regarding the proposed merger between Aker BioMarine ASA ("AKBM"), the transferor company, and Aker Seafoods Holding AS ("AKSH") the transferee company, where the shareholders in AKBM (except AKSH) will receive consideration shares in Aker ASA ("AKER") (the "Merger"). AKBM has today, Friday 9 November 2012, held an extraordinary general meeting regarding the Merger. The proposal was approved by the general meeting.

Aker BioMarine ASA Q3 2012 presentation (05.11.12)

In the third quarter of 2012, Aker BioMarine achieved its best financial results to date. Earnings before depreciation and amortization (EBITDA) were NOK 29 million, and earnings before tax (EBIT) were NOK 39 million. Aker BioMarine achieved another landmark event: sales of Superba™ Krill exceeded 100 metric tons for the first time, ending on a total of 106 metric tons.

For more information, please look at Aker BioMarine‘s Q3 2012 report and presentation.

Presentation of Q3 2012 results (31.10.12)

Aker BioMarine ASA will publish its interim report for 3th quarter of 2012 on Monday, November 5, 2012. Representatives from the company will be present.

Approval of merger plan by the board in Aker BioMarine ASA – notice for extraordinary general meeting (08.10.12)

Reference is made to the stock exchange announcements issued by AKER ASA ("AKER") and Aker BioMarine ASA ("AKBM") on 12 September 2012 regarding the proposal for a merger between AKBM and Aker Seafoods Holding AS ("AKSH"), a wholly owned subsidiary of AKER.

The board of directors of AKBM and AKSH have today approved and entered into the merger plan for the merger between AKBM and AKSH, with consideration shares in AKER. AKER has given its adherence to the merger plan.

Minutes from extraordinary general meeting (03.10.12)

Aker BioMarine ASA has today on October 3 2012 held an extraordinary general meeting. All proposals to the extraordinary general meeting were approved.

Advisors elected to advice the board of directors related to proposed merger with Aker ASA (19.09.12)

Reference is made to the stock exchange release of September 11 2012 regarding the proposal from Aker ASA to merge Aker BioMarine ASA with a wholly owned subsidiary of Aker ASA.

The board of directors has today elected Swedbank First Securities and Carnegie as financial advisors in connection with the merger. The advisors shall prepare a fairness opinion regarding the merger and the proposed exchange ratio, and also assist the the board in general in connection with the merger. The board has also elected the law firm Wikborg Rein as legal advisor.

Notice of extraordinary general meeting (12.09.12)

The shareholders of Aker BioMarine ASA are invited to attend an extraordinary general meeting to be held on Wednesday 3 October 2012 at 10:00 hrs at Felix Conference Centre, Bryggetorget 3 (Aker Brygge), N-0250 Oslo, Norway.

Aker propose to merge with Aker BioMarine (12.09.12)

On September 11, 2012 Aker BioMarine ASA ("AKBM") board of directors received a proposal from Aker ASA for a merger between AKBM and a wholly owned subsidiary of Aker ASA.

The minority shareholders of AKBM will be offered consideration in the form of shares in Aker ASA. Aker has proposed that the conversion ratio in the merger is based on a Aker BioMarine share price of NOK 1,20 which represent a premium of 17 percent to close on September 11, 2012. Based on the proposed conversion rate, Aker BioMarine shareholders will receive 0.006486 Aker ASA shares for each Aker BioMarine share they own.

The Aker BioMarine board will evaluate the proposal. The chairman of the board, Kjell Inge Røkke, has conflicted interests in this matter and will as such not participate in the board discussions. The board of directors will summon an extraordinary general meeting to elect an independent deputy board member.

Aker BioMarine ASA Q2 2012 presentation (13.08.12)

In the second quarter of 2012, Aker BioMarine achieved the highest quarterly sales of Superba™ Krill to date with 74 metric tons. Aker BioMarine is experiencing strong demand growth for both its dietary supplement Superba™ Krill and the feed ingredient Qrill™ and thus is upwardly adjusting the company’s 2012 sales guidance. Further, the company is considering alternatives for significantly increasing production capacity for Superba™Krill oil.

For more information, please look at Aker BioMarine‘s Q2 2012 report and presentation.

Presentation of Q2 2012 results (08.08.12)

Aker BioMarine ASA will publish its interim report for 2th quarter of 2012 on Monday, August 13, 2012. Representatives from the company will be present.

The presentation will be held at:

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its 2th quarter 2012 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Aker BioMarine Exec Matts Johansen Promoted to COO (08.05.12)

Aker BioMarine Antarctic announced today the promotion of Matts Johansen to the newly created position as Chief Operating Officer. Johansen has served as Executive Vice President of Marketing and Sales since October 2009. During his tenure he has overseen significant salesgrowth in North America and Europe, and the development of the Asian markets in paralell with regulatory filings.

Aker BioMarine ASA Q1 2012 presentation (07.05.12)

New and large customers in important markets contribute to continuous growth in sales of Superba™ Krill. Krill oil constitutes 7.9% of all omega-3 products sold in the US. Sales prices for Qrill™ Aqua are still increasing, and all planned production for 2012 is committed to customers. A distribution agreement for Qrill™ Pet with a significant player in the Pet-Food market in Europe has been signed.

For more information, please look at Aker BioMarine‘s Q1 2012 report and presentation.

Presentation of Q1 2012 results (02.05.12)

Aker BioMarine ASA will publish its interim report for first quarter of 2012 on Monday, May 7, 2012. Representatives from the company will be present.

The presentation will be held at:

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its first quarter 2012 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Annual General Meeting (13.04.12)

Aker BioMarine ASA has today on 13 April 2012 held its Annual General Meeting. All proposals to the Annual General Meeting were approved.

Norwegian and English copies of the minutes of the meeting are attached. Please also find attached the presentation held at the Annual General Meeting.

Registration of new shares in rights offering (12.04.12)

Reference is made to previous announcements in respect of the final result of the offering of new shares in Aker BioMarine ASA (the "Rights Offering"). The share capital increase pertaining to the new shares issued through the Rights Offering was today registered with the Norwegian Registry of Business Enterprises (Nw. Foretaksregisteret). After the registration, the registered share capital of Aker BioMarine ASA is NOK 1,172,776,152 comprising of 1,172,776,152 shares each with a par value of NOK 1.00.

For further information, please contact:
Fredrik Nygaard, CFO and IR contact, Aker BioMarine, tel +47 24 13 00 00

Change in announcement date for the first quarter 2012 financial results (11.04.12)

The company has decided to change the announcement date for the first quarter 2012 financial results to May 7 2012. The original announcement date was May 11 2012.

Notification of trade (03.04.12)

With reference to the share issue of Aker BioMarine ASA, which was approved by
the general assembly on 8 March 2012, Aker Seafoods Holding AS has been
allocated shares for exercised subscription rights according to the principles
set out in the prospectus.
Aker Seafoods Holding AS subscribed to 187,242,497 new shares at a subscription
price of NOK 1.15 per share and has been allocated 187,242,497 shares. Following
completion of the rights offering, Aker Seafoods Holding AS will own a total of
1,010,130,905 shares, i.e., 86,13% of the outstanding shares.

NOTIFIABLE TRADE (03.04.12)

Mr. Hallvard Muri, CEO in Aker BioMarine ASA, has through his company CAAC AS, entered into a total return swap (TRS) with 1 066 607 underlying shares in Aker BioMarine ASA with strike 1.2793 and close date 24.01.2014. Prior to the TRS agreement, CAAC AS had TRS exposure against 4 687 500 shares in Aker BioMarine ASA. Total exposure including the TRS agreement is 5 754 107 shares. In addition, Mr Muri owns 805 352 share through his company ACCA AS.

NOTIFIABLE TRADE (03.04.12)

Reference is made to the rights offering in Aker BioMarine which was approved by the extra ordinary shareholder meeting on March 8, 2012. The following primary insiders have been allocated new shares in accordance with the allocation principles described in the prospectus dated March 13, 2012

Final result of the rights offering (03.04.12)

Reference is made to the notice to the stock exchange dated 29 March 2012. The allocation from the rights offering, which closed on 28 March 2012 at 17:30, was concluded by the Board of Aker BioMarine ASA on 3 April 2012.

AKBM - Preliminary results of the rights offering (29.03.12)

Reference is made to the prospectus dated 13 March 2012 and the supplemental prospectus dated 21 March 2012 in relation to the rights offering of 217,391,304 offered shares in Aker BioMarine ASA at subscription price NOK 1.15 per share.

The subscription period for the rights offering ended 28 March 2012 and the preliminary subscription result shows that the rights offering was oversubscribed by approximately 4 per cent.

The allocation of offered shares is expected to take place on or about 3 April 2012, with payment for the allocated shares on 11 April 2012.

For further information, please contact:
Fredrik Nygaard, CFO and IR contact, Aker BioMarine, tel.: +47 24 13 00 00

Mandatory notification of trade (28.03.12)

Tore Heldrup Rasmussen, member of the board of directors of Aker BioMarine ASA, has today through his company Heldrup AS sold his 29,241 subscription rights in Aker BioMarine ASA at NOK 0.03 per subscription right. Tore Heldrup Rasmussens holds 510 663 shares in Aker BioMarine and no subscription rights after the transaction, in addition to the 86 956 shares subscribed for in the share issue with closing subscription period today, 28 March 2012.

Mandatory notification of trade (28.03.12)

Aker Seafoods Holding AS owns 822,888,408 shares in Aker BioMarine ASA, which amounts to 86.13% of all outstanding shares in the company. Aker ASA controls 100% of Aker Seafoods Holding AS.

With reference to the upcoming share issue in Aker BioMarine ASA, Aker Seafoods Holding AS has, on 28 March 2012, exercised all its subscription rights. This means that Aker Seafoods Holding AS has subscribed to 187,242,497 shares. The subscription price is NOK 1.15 per share. Aker Seafoods Holding AS has underwritten the rights offering and the number of shares Aker Seafoods Holding AS will own is thus dependent upon the result of the rights offering. Aker Seafoods Holding AS will minimum own 1,010,130,905 shares upon completion of the rights offering.

NOTIFIABLE TRADE (28.03.12)

Mr. Bjørn Flatgård, deputy chairman in Aker BioMarine ASA, has today exercised 37 320 subscription rights and subscribed for 37 320 new shares in Aker BioMarine ASA at a subscription price of NOK 1,15 per new share. Mr. Flatgård currently owns 164 017 shares, but will own 201 337 shares subject to completion of the share issue.

AKBM S – Last day of listing (28.03.12)

Last day of listing for the subscription rights in Aker BioMarine ASA is today, 28 March 2012.

Any subscription rights not exercised or sold by the expiry of the subscription period will lapse and cease to carry any value.

Holders of allotted or acquired subscription rights must, in order to subscribe for offered shares, deliver the correctly completed subscription form to Arctic Securities ASA by email to settlement@arcticsec.no or by fax on +47 21 01 31 36 within 28 March 20120 at 17:30 (CET). Subscribers who are Norwegian nationals may also subscribe for offered shares via the internet at www.arcticsec.no. For further information, see the prospectus dated 13 March 2012 and supplemental prospectus dated 21 March 2012.

Notice of Annual General Meeting (23.03.12)

The shareholders in Aker BioMarine ASA are invited to attend the Annual General Meeting to be held on Friday 13 April 2012 at 10.00 hrs at Felix Conference Centre, Bryggetorget 3, Aker Brygge, Oslo, Norway.

Please find attached a Notice of Annual General Meeting in Aker BioMarine ASA, the attendance ballot and the English Annual Report 2011 (Norwegian version will be published on the company’s webpage soon).

The notice of the annual general meeting and attendance ballot will be sent to all shareholders on March 23.

In addition, please find enclosed the Proposal from the Nomination Committee.

The attachments and proposed general meeting resolutions will also be made available on the company’s webpage www.akerbiomarine.com

Notice of Annual general meeting and Attendance ballot

Annual report 2011

Proposed general meeting resolutions

Proposal from the Nomination Committee and CV

Supplementary Prospectus (21.03.12)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN

Reference is made to announcement dated 16.03.2012.

The Financial Supervisory Authority of Norway has approved a supplemental prospectus to the prospectus dated 13.03.2012 concerning information as set out in announcement referred to above.

Investors that have applied for offered shares in the rights offering before the publication of the supplemental prospectus have the right to withdraw their application within two Norwegian business days after the publication of the supplemental prospectus, cf. Section 7-21(2) of the Norwegian Securities Trading Act (i.e. prior to 17:30 hours CET on 23 March 2012). Such withdrawal is made by contacting the manager Arctic Securities via telephone +47 21 01 31 00, fax +47 21 01 31 36 or through email at settlement@arcticsec.no.

Temporarily stop in Saga Sea operations (16.03.12)

Aker BioMarine’s krill harvesting vessel Saga Sea has sailed to the Falkland Islands after incurring an injury on its propulsion system. The injury occurred in connection with at-sea transshipment. The repair work is ongoing and the company expects that the work will be completed within a few days so that Saga Sea will return to operations during next week. After the season, the vessel will be docked for further inspection. The company expects that the repair costs will be covered by insurance. There were no personal injuries or emissions in connection with the injury.

For further information, please contact:
Hallvard Muri, CEO, Aker BioMarine +47 24 13 00 00

Approved Prospectus (13.03.12)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN

The Financial Supervisory Authority of Norway has approved the following prospectus:

Prospectus for rights offering and subsequent listing of 217,391,304 new shares (the "Offered Shares") each with a par value of NOK 1.00 at a subscription price of NOK 1.15 per Offered Share (the “Prospectus”)

AKBM - Ex subscription rights 9 March (09.03.12)

The shares in Aker BioMarine ASA will be traded exclusive subscription rights as of today 9 March 2012.

For further information, please note the announcements from Aker BioMarine ASA of 16 February 2012 and 8 March 2012.

For further information, please contact:
Fredrik Nygaard, CFO and IR contact, Aker BioMarine, tel +47 24 13 00 00

Last trading day inclusive subscription rights (08.03.12)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN

The shares in Aker BioMarine ASA will as of Friday, 9 March 2012, be traded exclusive subscription rights to participate in the rights offering adopted in today‘s extraordinary general meeting. Today, Thursday 8 March 2012, will thus be the last trading day inclusive subscription rights.

Extraordinary General Meeting (08.03.12)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN

Aker BioMarine ASA has today on 8 March 2012 held an Extraordinary General Meeting. All proposals to the Extraordinary General Meeting were approved, including the rights offering in Aker BioMarine ASA as proposed by the board of directors.

Epax appoints Ola Snøve as CEO (01.03.12)

The Board of Directors of Epax AS has appointed Ola Snøve as CEO effective immediately. Mr. Snøve replaces Terje Bakken.

Please find enclosed press release from Epax.

Extraordinary General Meeting (16.02.12)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN

Reference is made to the stock exchange notice dated 28 November 2011, regarding a possible share capital increase in Aker BioMarine ASA. The Board of Directors has resolved to propose a NOK 250 million rights issue in order to, among other things, finance the ongoing upgrade of Antarctic Sea (formerly Thorshøvdi), repay the company‘s bridge loan from Aker ASA, and finance potential follow-up investments in Trygg Pharma and general corporate purposes.

Aker BioMarine ASA Q4 2011 presentation (16.02.12)

Fourth quarter 2011 was the best-ever for Aker BioMarine so far, with Superba™ Krill sales of 70 MT and a total revenue of NOK 101 million.

For more information, please look at Aker BioMarine‘s Q4 2011 report and presentation.

Presentation of Q4 2011 results (13.02.12)

Aker BioMarine ASA will publish its interim report for fourth quarter of 2011 on Thursday, February 16, 2012. Representatives from the company will be present.

The presentation will be held at:

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its fourth quarter 2011 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

US Patent Office to re-exam Neptune patent (22.12.11)

On December 19, 2011, the United States Patent and Trademark Office granted Aker BioMarine‘s request for reexamination of US patent number 8,030,348 assigned to Neptune Technologies & Bioressources. The reexamination was granted on all 21 claims of the patent and in view of multiple references presented to the USPTO by Aker BioMarine.

Aker BioMarine’s financial calender 2012 (30.11.11)

Aker BioMarine’s financial calender for 2012 is as follows:

4th quarter results 2011/preliminary annual result 2011: February 16, 2012
Annual General Meeting: April 13
1st guarter results 2012: May 11
2nd quarter results 2012: August 13
3rd quarter results 2012: November 5

The dates are subject to change.

Mandatory notification of trade (29.11.11)

Aker Seafoods Holding AS, a wholly owned subsidiary of Aker ASA, has purchased 27,000,000 shares in Aker BioMarine ASA at a price of NOK 1.48427 per share. The new shareholding is 822.888.408, which represents 86.13% of the total shares outstanding.

Aker Capital AS, a wholly onwed subsidiary of Aker ASA, has settled a total return swap with exposure to 26,505,447 shares in Aker BioMarine ASA. After the transaction, Aker Capital AS does not have any exposure to shares in Aker BioMarine ASA.

Postponed execution of planned share issue (28.11.11)

In its third quarter report, Aker BioMarine announced its plan to issue new shares in range NOK 200 – 250 million in order to finance, among other, the rebuild of Antarctic Sea (formerly Thorshøvdi). Pursuant to discussions with its largest shareholder Aker ASA, Aker BioMarine has decided to postpone the share issue to first quarter 2012. Until the execution of the share issue, Aker ASA will provide up to NOK 166 million in bridge financing which equals Aker ASA’s pro rata share of a NOK 200 million share issue. The interest rate is based on arms’ length principle and set to NIBOR plus 1,50% p.a.

For more information, please contact:
Fredrik Nygaard, CFO Aker BioMarine: + 47 2413 00 00
Hallvard Muri, CEO Aker BioMarine: +47 24 13 00 00

Epax reports interim results from the phase III study on AKR 963 (23.11.11)

Epax, a company that Aker BioMarine owns 50/50 together with Lindsay Goldberg, today reported that the company’s pharmaceutical product, AKR 963, met the primary endpoints in the ongoing phase III clinical trial. The press release from Epax is attached.

NOTIFIABLE TRADE (15.11.11)

Mr. Tim de Haas, Director of Business Development in Aker BioMarine ASA, has entered into a total return swap (TRS) with 345,000 underlying shares in Aker BioMarine ASA with strike 1,6626 and close date 24.01.2014. The TRS agreement was made today. Prior to the TRS agreement, Tim de Haas owned 19,500 shares in Aker BioMarine ASA. Total exposure including the TRS agreement is 364,500 shares.

Aker BioMarine ASA Q3 2011 presentation (02.11.11)

In the third quarter of 2011, Aker BioMarine carried out strategic measures to ensure increased harvesting capacity that resulted in the acquisition of a second krill vessel, Thorshøvdi, in October 2011. Renamed Antarctic Sea, the vessel is scheduled to enter operations in late February 2012, following a comprehensive upgrade to ensure stable operations and increased harvesting capacity.

For more information, please look at Aker BioMarine‘s Q3 2011 report and presentation. Please find also EPAX company presentation.

Presentation of Q3 2011 results (27.10.11)

Aker BioMarine ASA will publish its interim report for third quarter of 2011 on Wednesday, November 2, 2011. Representatives from the company will be present. In addition, Terje Bakken, CEO of Epax (former Trygg Pharma), will give a company presentation of the Epax Group.

The presentation will be held at:

Acquisition of Thorshøvdi (21.10.11)

Aker BioMarine entered into an agreement with Krillsea Group AS on 18 October 2011 regarding an acquisition of the krill fishing vessel Thorshøvdi for approximately NOK 138.9 million. The agreement was consummated on 20 October 2011.

Purchase of vessel Thorshøvdi (18.10.11)

Aker BioMarine has entered into an agreement with Krillsea Group AS to acquire the vessel Thorshøvdi for approximately NOK 138.9 million. As part of the agreement, all creditors of Krillsea Group AS with first, second, or third priority mortgage in the vessel has agreed to release such security. The agreement will be consummated as soon as possible.

For further information regarding Aker BioMarine, please contact:
Hallvard Muri, CEO, Aker BioMarine, tel: +47 24 13 00 00
Fredrik Nygaard, CFO and IR contact, Aker BioMarine, tel.: +47 24 13 00 00

Aker BioMarine files for Patent Reexamination in the U.S. against Neptune Patent (04.10.11)

Aker BioMarine has today filed with the United States Patent and Trademark Office (“USPTO”) a request for reexamination of all claims in Neptune‘s recently-issued U.S. Patent Number 8,030,348. Aker BioMarine shows in its request that extractions of krill performed before Neptune‘s purported invention produced oils containing these phospholipids, although the USPTO was not previously informed of these facts, was not provided with copies of the relevant publications, and was not informed of proceedings in the European patent office in which Neptune‘s related European patent was ruled invalid.

Acquisition of debt (21.09.11)

Aker BioMarine has today entered into an agreement with Innovasjon Norge regarding an acquisition of the loans Innovasjon Norge has provided to Krillsea Group AS with related securities. The agreement will be consummated immediately.

Offer to purchase krill trawl vessel rejected (16.09.11)

The bond holders of Krillsea Group AS has today rejected the offer from Aker BioMarine to acquire the krill trawl vessel Thorshøvdi as further described in a stock release issued September 9 2011. Aker BioMarine acknowledges the bond holders’ decision and the company has now withdrawn the offer to purchase Thorshøvdi.
Aker BioMarine will now actively pursue other opportunities to get a krill trawl license for another vessel.

For further information regarding Aker BioMarine, please contact:

Hallvard Muri, CEO, Aker BioMarine, tel: +47 24 13 00 00
Fredrik Nygaard, CFO and IR contact, Aker BioMarine, tel.: +47 24 13 00 00

Offer to purchase krill trawl vessel (09.09.11)

Aker BioMarine has submitted a conditional offer to acquire the krill trawl vessel Thorshøvdi with its krill trawl license from Krillsea Group AS for a purchase price of NOK 130 000 000 free from encumbrances. A sale of the vessel is conditional upon consent from the bond holders of Krillsea Group AS. It has been decided to summon a bondholders meeting to request for consent to the sale.

Notification of trade (29.08.11)

Aker Capital AS has renewed a total return swap with 26,505,447 underlying shares in Aker BioMarine ASA. Close is 29 November 2011. Strike NOK 1.5537 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 795,888,408 shares in Aker BioMarine ASA, i.e. 83.3%.

Notification of trade (17.08.11)

Øystein Egner, Business Controller i Aker BioMarine ASA, har i dag kjøpt
16 305 aksjer til snittkurs 1,60 pr. aksje. Total beholdning etter dette
er 50 000 aksjer i Aker BioMarine ASA.

Aker BioMarine ASA Q2 2011 presentation (15.08.11)

In the second quarter of 2011, Aker BioMarine achieved record sales of Superba™ Krill and the company expanded its agreement to supply Schiff Nutrition International. Aker BioMarine has completed a comprehensive staff recruitment process and is increasing its focus on process and product development.

For more information, please look at Aker BioMarine‘s Q2 2011 report and presentation.

Presentation of Q2 2011 results (10.08.11)

Aker BioMarine ASA will release its interim report for the 2th quarter 2011 on Monday August 15, 2011. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its 2th quarter 2011 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Aker BioMarine strengthens management team (06.07.11)

Aker BioMarine has employed Mr. Peter Svensson as Executive Vice President with responsibility for onshore manufacturing. Mr. Svensson will strengthen the management team with valuable knowledge and competence to develop new products and production processes. Mr. Svensson has spent his entire career with Fresenius Kabi in different management positions and has a unique background from production and process development relating to lipids and emulsions.

SCHIFF NUTRITION INTERNATIONAL AND AKER BIOMARINE SIGN LONG-TERM KRILL OIL SUPPLY AGREEMENT - Plan to Collaborate on Future Innovations - (06.07.11)

Aker BioMarine (OSE: AKBM) and Schiff Nutrition International (NYSE:WNI) expanded their supply agreement through at least June 2016 to provide Schiff high quality Aker BioMarine krill oil. Further, Schiff is granted certain exclusive sales rights, and the parties have agreed to collaborate on future innovations.

Application for krill trawl license rejected (28.06.11)

Aker BioMarine has today received the rejection of the application for a Norwegian krill license for the operation of the vessel Antarctic Navigator in the Southern Ocean. As described in the stock exchange release of April 29 2011, the company applied for a second krill trawl license.

Trygg Pharma acquires factory in the UK (16.06.11)

See attached press release from Trygg Pharma. Trygg Pharma acquires a manufacturing facility from Lundbeck Pharmaceuticals Ltd. for DKK 120 million. The site is located in Seal Sands, Middlesbrough, UK.

Significant supply agreement for Aker BioMarines Qrill™ (19.05.11)

Aker BioMarine has signed a 5-year supply agreement for the premium value ingredient Qrill™ with BioMar, one of the world’s leading aquaculture feed producers. In the agreement, Aker BioMarine will annually supply a minimum of 3,000 tons Qrill™. This is approximately 30% of Aker BioMarines annual production of Qrill™ today. The price for Qrill™ is set with a reference to comparable international raw material prices, with an additional premium for the added value of Qrill™.

Intensifying growth and developing new markets and products (09.05.11)

Superba™ Krill sales continued to increase in the first quarter of 2011 as the company signs its first major contract in China. Aker BioMarine is moving ahead on several fronts, including a comprehensive staff recruitment process and a license application for deployment of a second krill harvesting vessel, Antarctic Navigator.

For more information, please look at Aker BioMarine‘s Q1 2011 report and presentation.

Presentation of Q1 2011 results (04.05.11)

Aker BioMarine ASA will release its interim report for the 1th quarter 2011 on Monday 9, 2011. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its 1th quarter 2011 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Application for krill trawl licence (29.04.11)

Aker BioMarine has today delivered an application for krill trawl licence in the Southern Ocean with the vessel Antarctic Navigator. Antarctic Navigator is owned by a wholly owned subsidiary of Aker ASA, but may be acquired by Aker BioMarine at market value, if Aker BioMarine is awarded a krill trawl licence.

Notification of trade (28.04.11)

Aker Capital AS has renewed a total return swap with 26,505,447 underlying shares in Aker BioMarine ASA. Close is 29 August 2011. Strike NOK 2.3462 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 795,888,408 shares in Aker BioMarine ASA, i.e. 83.3%.

Annual General Meeting (05.04.11)

Aker BioMarine ASA has today on 5 April 2011 held its Annual General Meeting. All proposals to the Annual General Meeting were approved.

Norwegian and English copies of the minutes of the meeting are attached. Please also find attached the presentation held at the Annual General Meeting.

TRYGG PHARMA APPOINTS TERJE BAKKEN AS CEO (01.04.11)

Attached is the press release from Trygg Pharma Holding AS.

Nomination Committee Recommendations (31.03.11)

Enclosed please find recommendations from Aker BioMarine ASA’s Nomination committee in connection with the company’s Annual General Meeting on 5 April 2011. In addition, enclosed also find presentation of Nomination committee’s recommended new member.

Notification of Proxies (31.03.11)

Investment director in Aker ASA, Ola Snøve, has as of March 31, 2011 received proxies to vote at Aker BioMarine ASA’s annual general meeting to be held on April 5, 2011 for a total of 795,888.408 shares. This equals 83.31 percent of the total shares and voting rights in Aker BioMarine ASA.

The proxies are without voting instructions and are only valid for the general meeting specified above.

Breakthrough for Superba™ Krill in China (22.03.11)

Aker BioMarine has today signed a major agreement with a Chinese manufacturer of dietary supplements with strong distribution capabilities in China. In the five year agreement, Aker BioMarine will be the exclusive supplier of krill products to the customer. The customer will launch Superba™ Krill into several channels in the Chinese market.

Notice of Annual General Meeting (15.03.11)

The shareholders in Aker BioMarine ASA are invited to attend the Annual General Meeting to be held on Tuesday 5 April 2010 at 10.00 hrs at Felix Conference Centre, Bryggetorget 3, Aker Brygge, Oslo, Norway.

Aker BioMarine’s best year so far (18.02.11)

Significant Trygg Pharma value potential was realized in the fourth quarter of 2010 through the partnership agreement with Lindsay Goldberg. The year 2010 was Aker BioMarine’s best so far.
For more information, please look at Aker BioMarine‘s Q4 2010 report and presentation.

Presentation of Q4 2010 results (14.02.11)

Aker BioMarine ASA will release its interim report for the 4th quarter 2010 on February 18, 2011. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its 4th quarter 2010 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

NOTIFIABLE TRADE (25.01.11)

Mr. Hallvard Muri, CEO in Aker BioMarine ASA, has through his company ACCA AS, entered into a total return swap (TRS) with 4,687,500 underlying shares in Aker BioMarine ASA with strike 1.9007 and close date 24.01.2014. The TRS agreement was made yesterday after the close of Oslo Stock Exchange. Prior to the TRS agreement, ACCA owned 656,069 shares in Aker BioMarine ASA. Total exposure including the TRS agreement is 5,343,569 shares.

Aker BioMarine’s financial calender for 2011 is as follows: (21.12.10)

4th quarter results 2010/preliminary annual result 2010: February 18, 2011
Annual General Meeting: April 5
1st guarter results 2011: May 9
2nd quarter results 2011: August 15
3rd quarter results 2011: November 2

Completion of the sale of 50% of the shares in Trygg Pharma Holding AS to Lindsay Goldberg and the acquisition of EPAX Holding AS from Austevoll Seafood ASA (17.11.10)

Reference is made to the stock exchange notice of 3 September 2010 regarding Lindsay Goldberg’s acquisition of 50 % of the shares in a newly established joint venture company, Trygg Pharma Holding AS, from Aker BioMarine ASA, the stock exchange notice of 3 September 2010 regarding the purchase by Trygg Pharma AS (a wholly owned subsidiary of Trygg Pharma Holding AS) of 100% of the shares in Epax Holding AS from Austevoll Seafood ASA, and the prospectus dated 29 September 2010 prepared in connection with the rights issue completed in Aker BioMarine ASA.
Lindsay Goldberg’s acquisition of 50% of the shares in Trygg Pharma Holding AS from Aker BioMarine ASA and the acquisition by Trygg Pharma AS of 100% of the shares in Epax Holding AS from Austevoll Seafood ASA have been completed in accordance with the agreements entered into between the parties, as further described in the abovementioned stock exchange notices and the prospectus.

New share capital registered (15.11.10)

Reference is made to the stock exchange notices of 20 October and 12 November 2010. The new shares issued in the rights offering in Aker BioMarine ASA are now registered in the Register of Business Enterprises http://www.brreg.no/english/registers/business/. The share capital in the company is now NOK 955 384 848 with a total number of shares of 955 384 848, each with par value NOK 1.00. It is expected that the new shares will be registered on each subscribers VPS account today, and that the new shares will be tradable on the Oslo Stock Exchange from today, 15 November 2010.

All conditions for the acquisition of EPAX Holding AS are fulfilled and the rights offering in AKBM will be registered (12.11.10)

Reference is made to the stock exchange notice of 20 October 2010 and the prospectus dated 29 September 2010. All conditions for the acquisition of EPAX Holding AS from Austevoll Seafood ASA are fulfilled, and the rights offering in AKBM will be registered in the Norwegian Register of Business Enterprises as soon as practically possible. It is expected that the new shares will be registered in the Norwegian Register of Business Enterprises on 15 November 2010.

Notification of trade (04.11.10)

Mr. Martin H. Arnholdt, Group controller in Aker BioMarine ASA, has today
purchased 22 500 shares at an average of NOK 1,52 per share.
Following this transaction Mr. Arnholdt owns 22 500 shares in Aker BioMarine ASA.

Sales growth and joint venture partnership (03.11.10)

Aker BioMarine continued its favorable development in the third quarter of 2010, enjoying further EBITDA growth and the company’s first-ever positive cash flow from operations. Significant Trygg Pharma value potential was promoted through a partnership entered into with US-based investor Lindsay Goldberg.

For more information, please look at Aker BioMarine‘s Q3 2010 report and presentation.

Presentation of Q3 2010 results (28.10.10)

Aker BioMarine ASA will release its interim report for the 3th quarter 2010 on November 3, 2010. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its 3th quarter 2010 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Trygg Pharma announces start of clinical study (28.10.10)

Trygg Pharma, Inc., et datterselskap av Aker BioMarine, rekrutterer nå pasienter til en klinisk fase III-studie som skal undersøke effekten av AKR 963 – en legemiddelkandidat selskapet har utviklet - for behandling av pasienter med alvorlig hypertriglyseridemi.

De som er interessert kan snart se til www.clinicaltrials.gov for mer informasjon om inklusjonskriterier for studien eller medvirkende legesenter.

For ytterligere informasjon, vennligst kontakt:
Fredrik Nygaard, CFO og IR-ansvarlig, Aker BioMarine, tel: 24 13 00 00
Aaron Kramer, CEO, Trygg Pharma, tel: 24 13 00 00

Notifiable Trade (20.10.10)

Aker Capital AS has renewed a total return swap with 20,200,171 underlying shares in Aker BioMarine ASA and increased its exposure with 6,305,276 shares in connection with the rights offering in Aker BioMarine. Total exposure is 26,505,447 and close is 20 January 2011. Strike NOK 1.5210 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 795,888,408 shares in Aker BioMarine ASA, i.e. 83.3%.

Notifiable Trade (20.10.10)

With reference to the share issue of Aker BioMarine ASA, which was approved by the general assembly on 24 September 2010, Aker Seafoods Holding AS has been allocated shares for exercised subscription rights according to the principles set out in the prospectus.

Aker Seafoods Holding AS subscribed for 189,330,731 new shares at a subscription price of NOK 1.10 per share and has been allocated 189,330,731 shares. Following completion of the rights offering, Aker Seafoods Holding AS will own a total of 795,888,408 shares, i.e., 83.3% of the outstanding shares.

NOTIFIABLE TRADE (20.10.10)

Reference is made to the rights offering in Aker BioMarine which was approved by the extra ordinary shareholder meeting on September 24, 2010. The following primary insiders have been allocated new shares in accordance with the allocation principles described in the prospectus dated September 29, 2010.

AKBM – Final results of the rights offering (20.10.10)

Reference is made to the notice to the stock exchange dated 15 October 2010. The allocation from the rights offering, which closed on 14 October 2010 at 17:30, was concluded by the Board of Aker BioMarine ASA on 20 October 2010.

AKBM – Preliminary results of the rights offering (15.10.10)

Reference is made to the prospectus dated 29 September 2010 in relation to the rights offering of 227,272,727 offered shares in Aker BioMarine ASA at subscription price NOK 1.10 per share.

The subscription period for the rights offering ended 14 October 2010 and the preliminary subscription result shows that the rights offering was oversubscribed by approximately 25 per cent.

The allocation of Offered Shares is expected to take place on or about 20 October 2010, with payment for the allocated shares on 25 October 2010.

For further information, please contact:
Hallvard Muri, president and CEO, Aker BioMarine, tel +47 24 13 00 00

AKBM S – Last day of listing (14.10.10)

Last day of listing for the Subscription Rights in Aker BioMarine ASA is today, 14th of October 2010.

Any Subscription Rights not exercised or sold by the expiry of the subscription period will lapse and cease to carry any value.

Holders of allotted or acquired Subscription Rights must, in order to subscribe for Offer Shares, deliver the correctly completed subscription form to Arctic Securities ASA by fax on +47 21 01 31 36 within 14th of October 2010 at 17:30. Subscribers who are Norwegian nationals may also subscribe for Offer Shares via the internet at www.arcticsec.no. For further information, see the prospectus dated 29th September 2010.

Notification of trade (11.10.10)

Aker Seafoods Holding AS owns 606,557,677 shares in Aker BioMarine ASA, which amounts to 83.31% of all outstanding shares in the company. Aker ASA controls 100% of Aker Seafoods Holding AS.

With reference to the upcoming share issue in Aker BioMarine ASA, Aker Seafoods Holding AS has, on 11 October 2010, exercised all its subscription rights. This means that Aker Seafoods Holding AS has subscribed to 189,330,731 shares. The subscription price is NOK 1.10 per share.

NOTIFIABLE TRADE (11.10.10)

Mr. Tore Heldrup Rasmussen, board member in Aker BioMarine ASA, has today, through his company Heldrup AS, exercised 121 479 subscription rights and subscribed for 121 479 new shares in Aker BioMarine ASA at a subscription price of NOK 1,1 per new share. Heldrup AS currently owns 389 184 shares, but will own 510 663 shares subject to completion of the share issue.

Approved prospectus (29.09.10)

The Financial Supervisory Authority of Norway has approved the following prospectus:

Prospectus for rights offering and subsequent listing of 227,272,727 new shares (the "Offered Shares") each with a par value of NOK 1.00 at a subscription price of NOK 1.10 per Offered Share

AKBM - Ex subscription rights 27 September (27.09.10)

The shares in Aker BioMarine ASA will be traded exclusive subscription rights as of today 27 September 2010.

See the announcements from Aker BioMarine ASA as of 3 September 2010 and 24 September 2010.

For further information, please contact:
Hallvard Muri, president and CEO, Aker BioMarine, tel +47 24 13 00 00
Fredrik Nygaard, CFO and IR contact, Aker BioMarine, tel +47 24 13 00 00

AKBM - Last trading day inclusive subscription rights (24.09.10)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN

Reference is made to today‘s stock exchange release regarding the approval of
the rights offering by the extraordinary general meeting of Aker BioMarine ASA. The shares in Aker BioMarine ASA will as of Monday, 27 September 2010, be traded exclusive subscription rights to participate in the rights offering adopted in today‘s extraordinary general meeting. Today, Friday 24 September 2010, will thus be the last trading day inclusive subscription rights.

Extraordinary General Meeting (24.09.10)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN

Aker BioMarine ASA has today on 24 September 2010 held an Extraordinary General Meeting. All proposals to the Extraordinary General Meeting were approved, including the rights offering in Aker BioMarine ASA as proposed by the board of directors.

Notification of trade (06.09.10)

Mr. Hallvard Muri, President & CEO in Aker BioMarine ASA, has today through his company ACCA AS purchesed 500.000 shares at an average of NOK 1,7036 per share. Following this transaction Mr. Muri owns 500.000 shares in Aker BioMarine ASA.

Proposed rights issue in Aker BioMarine (03.09.10)

The Board of Directors has resolved to propose a rights issue to finance Aker BioMarine ASA’s (“Aker BioMarine”) participation in the joint venture with Lindsay Goldberg LLC and the joint venture’s acquisition of Epax Holding AS from Austevoll Seafood ASA (cf. the separate notices from Aker BioMarine of today). The proposal will be presented to Aker BioMarine’s extraordinary general meeting on 24 September 2010.

Trygg Pharma acquires Epax from Austevoll Seafood (03.09.10)

Trygg Pharma AS – a company that will be jointly owned by Aker BioMarine ASA and an affiliate of Lindsay Goldberg LLC through a newly established joint venture company (cf. the separate notice of today) – has entered into an agreement to acquire 100% of the shares in Epax Holding AS (together with its subsidiaries “Epax”), a wholly owned subsidiary of Austevoll Seafood ASA. Epax is the world’s premier high concentrate omega-3 supplement manufacturer. Epax employs a total of 74 people.

Aker BioMarine and Lindsay Goldberg to form 50/50 joint venture (03.09.10)

An affiliate of Lindsay Goldberg LLC (“LG” or “Lindsay Goldberg”) – a New York-based private investment firm with approximately USD 10 billion of equity capital under management and a long-term investment horizon of up to 20 years – has entered into an agreement with Aker BioMarine ASA (“AKBM” or “Aker BioMarine”) to acquire 50% of all outstanding shares in a newly established joint venture company (“NewCo”) that will own Trygg Pharma AS and Natural Nutrition Development Ltd AS (“NND”), both wholly owned subsidiaries of Aker BioMarine. Lindsay Goldberg will pay up to NOK 280 million for the 50% stake in NewCo, of which NOK 140 million is paid upfront and another NOK 140 million is subject to certain development milestones.

Strong Superba™ Krill sales growth (06.08.10)

The growth continued for Aker BioMarine in the second quarter of 2010. Sales growth was strong, harvesting and production were good, and the Aker BioMarine Group recorded its first-ever EBITDA in the black. The Marine Stewardship Council (MSC) certification confirms that Aker BioMarine conducts sustainable krill harvesting.

For more information, please look at Aker BioMarine‘s Q2 2010 report and presentation.

Presentation of Q2 2010 results (30.07.10)

Aker BioMarine ASA will release its interim report for the 2th quarter 2010 on August 6, 2010. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its 2th quarter 2010 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Notification of trade (20.07.10)

Aker Capital AS has renewed a total return swap with 20,200,171 underlying shares in Aker BioMarine ASA. Close is 20 October 2010. Strike NOK 1.5219 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 75,068,382 shares in Aker BioMarine ASA, i.e. 83.3%.

Certified by the Marine Stewardship Council (MSC) (25.05.10)

Aker BioMarine has today received confirmation that its krill fisheries will be certified by the Marine Stewardship Council (MSC), an independent, global, non-profit organization that works to promote the best choices in sustainable seafood. In future purchases of Aker BioMarine’s SuperbaTM and QrillTM products, consumers can be assured that their Omega-3 rich krill products are harvested in an environmentally sustainable way.

Completion of share issue and refinancing (11.05.10)

Reference is made to the stock exchange notice published earlier today regarding the register of the new share capital in Aker BioMarine ASA. The rights offering in Aker BioMarine is now completed and the company has finalized the refinancing plan communicated in the stock exchange notices on February 8 2010 and March 10 2010.

New share capital registered (11.05.10)

Reference is made to the stock exchange notice of May 5 2010. The new shares issued in the rights offering in Aker BioMarine are now registered in the Register of Business Enterprises. The share capital is now NOK 728 112 121 with a total number of shares of 728 112 121, each with par value NOK 1.00.

It is expected that the new shares will be registered on each subscribers VPS account on or about May 11 2010, and that the new shares will be tradable on the Oslo Stock Exchange from today May 11 2010.

NOTIFIABLE TRADE (05.05.10)

Reference is made to the rights offering in Aker BioMarine which was approved by the annual general meeting on April 8 2010. The following primary insiders have been allocated new shares in accordance with the allocation principles described in the prospectus dated April 14 2010.

AKBM – Final results of the rights offering (05.05.10)

Reference is made to the notice to the stock exchange dated 30 April 2010. The allocation from the rights offering, which closed on 29 April 2010 at 17:30 has been concluded by the Board of Aker BioMarine ASA on 5 May 2010.

Notification of trade | Aker Capital AS (05.05.10)

Aker Capital AS, a wholly owned subsidiary of Aker ASA, has today entered into a total return swap with cash settlement on 17,700,171 underlying shares in Aker BioMarine ASA. Close is 20 July 2010 and strike NOK 1.0107 per share. Aker Capital AS has previously entered into a total return swap on 2,500,000 shares in Aker BioMarine ASA. Close is 20 July 2010 and strike NOK 3.2941 per share. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 606,557,677 shares in Aker BioMarine ASA, i.e., 83.3% of the outstanding shares.

Notification of trade | Aker Seafoods Holding AS (05.05.10)

With reference to the share issue of Aker BioMarine ASA, which was approved by the general assembly on 8 April 2010, Aker Seafoods Holding AS has been allocated shares for exercised subscription rights according to the principles set out in the prospectus.

Aker Seafoods Holding AS subscribed for 531,489,295 new shares at a subscription price of NOK 1 per share and has been allocated 531,489,295 shares. Following completion of the rights offering, Aker Seafoods Holding AS will own a total of 606,557,677 shares, i.e., 83.3% of the outstanding shares.

Preliminary results show that the rights offering was over-subscribed (30.04.10)

Reference is made to the prospectus dated 14 April 2010 in relation to the rights offering of minimum 586,000,000 shares and up to 638,000,000 offered shares in Aker BioMarine ASA at subscription price NOK 1.00 per share.

NOTIFIABLE TRADE (27.04.10)

Mr. Tore Heldrup Rasmussen, board member in Aker BioMarine ASA, has today, through his company Heldrup AS, exercised 341 018 subscription rights and subscribed for 341 018 new shares in Aker BioMarine ASA at a subscription price of NOK 1 per new share. Heldrup AS currently owns 48 166 shares, but will own 389 184 shares subject to completion of the share issue.

Notifiable trade – Aker Seafoods Holding AS (27.04.10)

Aker Seafoods Holding AS owns 75,068,382 shares in Aker BioMarine ASA, which amounts to 83.31% of all outstanding shares in the company. Aker ASA controls 100% of Aker Seafoods Holding AS.

Notification of trade (21.04.10)

Aker Capital AS has renewed a total return swap with 2,500,00 underlying shares in Aker BioMarine ASA. Close is 20 July 2010. Strike NOK 3.2941 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 75,068,382 shares in Aker BioMarine ASA, i.e. 83.3%.

Positive development throughout the value chain from harvesting to customer (20.04.10)

Aker BioMarine continued to advance in the first quarter of 2010 with revenue growth, good harvesting, and profit growth compared with the first quarter of 2009. Sales of Superba™ Krill were 27.9 metric tons (MT) in the first quarter of 2010; sales of the company’s high-value feed ingredient Qrill™ totaled 1,865 MT, up 60 percent from the corresponding first-quarter 2009 figure. Aker BioMarine produced 4,256 MT of Qrill™ in the quarter, up 146 percent from 1,729 MT in the first quarter of 2009.

For more information, please look at Aker BioMarine’s Q1 2010 report and presentation.

Presentation of Q1 2010 results (13.04.10)

Aker BioMarine ASA will release its interim report for the 1th quarter 2010 on April 20, 2010. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its 1th quarter 2010 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Ex subscription rights 9 April (09.04.10)

The shares in Aker BioMarine ASA will be traded ex subscription rights as of today 9 April 2010.

See announcement from Aker BioMarine ASA 8 April 2010

For further information, please contact:
Hallvard Muri, president and CEO, Aker BioMarine, tel +47 24 13 00 00
Fredrik Nygaard, CFO and IR contact, Aker BioMarine, tel +47 24 13 00 00

Breakthrough for Superba™ Krill in Europe (08.04.10)

Aker BioMarine has today signed a major agreement with a leading European manufacturer and brand of dietary supplements. In the five year agreement Aker BioMarine will be the exclusive supplier of Superba™ Krill to the customer. The customer will formulate Superba™ Krill oil into one of its existing products and thus will purchase significant volumes immediately.

Last trading day inclusive subscription rights (08.04.10)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN

Reference is made to today’s stock exchange release regarding the approval of the rights offering by the general meeting of Aker BioMarine ASA. The shares in Aker BioMarine ASA will as of tomorrow, 9 April 2010, be traded exclusive subscription rights to participate in the rights offering adopted in today’s general meeting.

Annual General Meeting (08.04.10)

Aker BioMarine ASA has today on 8 April 2010 held its Annual General Meeting. All proposals to the Annual General Meeting were approved, including the rights offering in Aker BioMarine as proposed by the board of directors.

The rights offering as proposed by the board of directors is described in the stock exchange notice dated 15 March 2010. Further information will be made available in a prospectus that is expected to be published on 15 April 2010.

Norwegian and English copies of the minutes of the meeting are attached. Please also find attached the presentation held at the Annual General Meeting.

Nomination Committee Recommendations (26.03.10)

Enclosed please find recommendations from Aker BioMarine ASA’s Nomination committee and presentation of the Board of Directors in connection with the company’s Annual General Meeting on 8 April 2010.

Aker BioMarine increases loan facility from majority owner (26.03.10)

Aker BioMarine and Aker ASA have today agreed to increase the short term loan facility announced September 15 with NOK 20 million. Since the loan agreement was entered into in September, Aker BioMarine has had a positive development with increased sales and a good start to fishing season. However, this has led to increased working capital financing need.

Change in announcement date for the first quarter 2010 financial results (18.03.10)

The company has decided to change the announcement date for the first quarter 2010 financial results to April 20 2010. The original announcement date was April 28 2010.

Notice of Annual General Meeting (18.03.10)

The shareholders in Aker BioMarine ASA are invited to attend the Annual General Meeting to be held on Thursday 8 April 2010 at 08.00 hrs at Felix Conference Centre, Bryggetorget 3, Aker Brygge, Oslo, Norway.

Please find attached a Notice of Annual General Meeting in Aker BioMarine ASA, the attendance ballot and the Annual Report 2009.

The notice of the annual general meeting with all relevant documents attached, including a print version of the 2009 annual report, will be posted to all shareholders on March 18.

The Nomination Committee recommendations will be made public through a press release and a notification to the Oslo Stock Exchange as soon as they are finalized.

Superba™ Krill med full sporbarhet fra fangst til forbruker (17.03.10)

I lys av oppslag i pressen rundt sporbarhet av omega-3 og spesielt fiskeoljer fra omstridte fiskerier i Vest-Sahara og Marokko vil Aker BioMarine klargjøre status for våre produkter og sporbarhetssystem.

Proposed Conditions for Share Issue (15.03.10)

NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR TO, JURISDICTIONS IN WHICH THE SHARE OFFERING IS PROHIBITED, INCLUDING USA, AUSTRALIA, CANADA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, JAPAN OR HONG KONG.

Understanding reached with bondholders (10.03.10)

Aker BioMarine has negotiated a solution with its bondholders to refinance the company’s NOK 750 million bond loan, which matures in May 2010. As previously announced, Aker will convert into equity its net receivables that are payable by Aker BioMarine, while the other bondholders have accepted a three-year extension of the loan’s maturity date for the remaining NOK 305 million of the loan in return for a 0.25 percentage point increase in the loan interest they will receive, provided that Aker issue a payment guarantee.

Aker BioMarine refinancing plan (08.02.10)

Aker BioMarine and its majority shareholder and largest creditor, Aker ASA, have prepared a refinancing plan for the company. The plan establishes a solid financial foundation for advancing Aker BioMarine’s business activities. The company is in discussions with key bondholders to secure their approval of the refinancing plan.

Aker BioMarine ASA Q4 2009 presentation (08.02.10)

Aker BioMarine continued its advances in the fourth quarter of 2009 with revenue growth and improved cash flow from operations. 24.8 metric tons (MT) of Superba™ Krill was sold in the fourth quarter; up 48 percent from the third quarter. Sales of the high-value feed ingredient Qrill™ grew 57 percent compared with the fourth quarter of 2008; the figure is down slightly from the third quarter of 2009.

For more information, please look at Aker BioMarine’s Q4 2009 report and presentation.

Presentation of Q4 2009 results (01.02.10)

Aker BioMarine ASA will release its interim report for the 4th quarter 2009 on February 8, 2010. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its 4th quarter 2009 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Neptune’s European krill composition patent revoked by the European Patent Office (15.12.09)

Neptune Technologies & Bioressources Inc’s (‘Neptune’) European Patent EP1417211B1 has been opposed by Aker BioMarine and the Israeli company Enzymotec. The filed oppositions were dealt with by the European Patent Office (‘EPO’) in a hearing in Munich on December 14th. EPO’s opposition division concluded the hearing to revoke Neptune’s European patent on the basis of insufficiency of disclosure.

Meldepliktig handel (14.12.09)

Aker Seafoods Holding AS har kjøpt 60.000 aksjer i Aker BioMarine ASA til kurs 9,73. Ny beholding er 75.068.382 aksjer, dvs. 83,31 % av totalt antall aksjer i Aker BioMarine.

Aker Capital AS har en total return swap med eksponering mot 2.500.000 aksjer i Aker BioMarine ASA. Forfall 20. januar 2010 Avregningskurs er 6, 991 pr. aksje.

Aker BioMarine awarded public grant for research on Superba™ Krill (10.12.09)

Aker BioMarine has been awarded a three-year NOK 8 million research grant from the Research Council of Norway’s Food Programme. The biotechnology company will use the funds to continue its ambitious documentation program on Superba™ Krill products. Aker BioMarine was one of five receivers out of an application pool of 37 companies.

Superba™ Krill Oil ready for the European market (10.12.09)

Aker BioMarine has been notified by the Finnish Food Safety Authority that Superba™ Krill Oil is now approved as Novel Food in the European Union. Consequently, Superba™ Krill Oil can be sold in all countries within the European Union.

Valensa International will use Superba™ Krill Oil for Joint Health and Eye Health products (08.12.09)

Norwegian biotechnology company Aker BioMarine has signed a long-term global supply agreement with Valensa International for the use of Superba™ in Krill Oil Joint Health and Eye Health products where Aker BioMarine will be the exclusive supplier of krill oil. Under the agreement, Aker BioMarine and Valensa will also jointly perform clinical studies to document the unique properties of Superba™ Krill Oil as an ingredient in Valensa’s patented and patent-pending formulations.

Ready to face Neptune in court (16.11.09)

Neptune Technologies & Bioresources, Inc. has sent out a press release saying that they have filed a patent infringement lawsuit against Aker BioMarine and its distributor Jedwards International in the U.S. District Court for the District of Massachusetts. In the press release, Neptune claims infringement of U.S. Patent No. 6,800,299.

Meldepliktig handel (30.10.09)

Aker Seafoods Holding AS har i dag kjøpt 350.889 aksjer i Aker BioMarine ASA til kurs 7,16. Selger er Aker Seafoods ASA. Ny beholding er 75.008.382 aksjer, dvs. 83,24 % av totalt antall aksjer i Aker BioMarine.

Aker Capital AS har en total return swap med eksponering mot 2.500.000 aksjer i Aker BioMarine ASA. Forfall 20. januar 2010. Avregningskurs er 6, 991 pr. aksje.

Aker BioMarine third quarter 2009 (28.10.09)

Aker BioMarine continued to advance in the third quarter of 2009, with strong Superba™ Krill sales growth and improved cash flow from operations. Sales of Superba™ Krill in third quarter was 16.8 metric tons (MT) which is 236 percent higher than second quarter. Sales of the high-value Qrill™ feed ingredient also rose sharply in the third quarter. Sales increased by 60 percent to 2 729 MT, up from 1 701 MT in the second quarter of 2009.
For more information, please look at Aker BioMarine’s Q3 2009 report and presentation.

Aker BioMarine strengthens US market position (28.10.09)

Mercola Group in the USA has selected the biotechnology company Aker BioMarine as its exclusive supplier of krill oil for its Mercola Advanced Nutrition Antarctic Pure Krill Oil products. The agreement provides entry into an important distribution channel for dietary supplements in the United States.

Superba Krill grows in Europe (28.10.09)

Aker BioMarine is experiencing strong and growing interest for the dietary supplement Superba™ Krill in the European market. The biotechnology company has recently applied for Novel Food approval of Superba™ Krill in the EU.

Presentation of Q3 2009 results (22.10.09)

Aker BioMarine ASA will release its interim report for the third-quarter on October 28, 2009. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its third-quarter 2009 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Court victory for Superba Krill (09.10.09)

Aker BioMarine and Superba Krill won. Orkla lost its court battle to block competition from the omega-3 based dietary supplement Superba Krill.

Seier til Superba Krill (09.10.09)

Aker BioMarine og Superba Krill vant. Orkla tapte kampen om å stanse konkurransen fra det omega-3 baserte kosttilskuddet Superba Krill.

Superba™ Krill Oil – beneficial effect on cholesterol (21.09.09)

A new study performed for the biotechnology company Aker BioMarine has demonstrated that Superba™ Krill Oil might be of benefit in individuals with metabolic syndrome and fatty liver. These results are important because they confirm previous findings.

Overraskende anklager fra markedsleder (17.09.09)

En større markedsføringskampanje for Aker BioMarines Superba™ Krill pågår for tiden i norske medier. Orkla-konsernet ved Axellus AS (tidligere Peter Møller AS) har i denne forbindelse begjært midlertidig forføyning med krav om midlertidig stans i markedsføringen av Superba™ Krill.

Ski champion Ole Einar Bjørndalen teams with Superba™ Krill (17.09.09)

The biotechnology company Aker BioMarine and the biathlon champion, Ole Einar Bjørndalen have signed a long-term cooperation agreement. Aker BioMarine’s Superba™ Krill brand is now a personal sponsor of the athlete who has won more competitions than any other skier.

Aker BioMarine borrows from majority owner (17.09.09)

The biotechnology company Aker BioMarine will borrow up to NOK 90 million from the company’s majority shareholder, Aker ASA. Up to NOK 50 million of the aforesaid loan can be drawn initially. Additional NOK 40 million will be made available once Aker BioMarine has presented and received Aker ASA’s approval of a comprehensive refinancing plan. The new loan will be secured by major company assets.

Exclusive Superba™ agreement in USA (02.09.09)

The biotechnology company Aker BioMarine has signed an agreement to be the exclusive supplier of the company’s Superba™ Krill Oil dietary supplement to the market leader Schiff Nutrition International. The agreement is a major breakthrough for Aker BioMarine in the US market.

Superba™ Krill direct sales to consumers in Norway (31.08.09)

Aker BioMarine is launching its new Superba™ Krill Concentrate dietary supplement on 1 September. The dietary supplement will be launched via a nationwide campaign in several media channels.

Notification of trade (21.08.09)

Aker Capital AS has renewed a total return swap with 2,500,00 underlying shares in Aker BioMarine ASA. Close is 20 October 2009. Strike NOK 6.2983 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 74,657,494 shares in Aker BioMarine ASA, i.e. 82.9%.

Solid start in USA for Superba Krill (11.08.09)

The biotechnology company Aker BioMarine shipped 15 metric tons (MT) of Superba Krill to the US market in the second quarter of 2009. Of this tonnage, 4.8 MT were sales recorded in the second quarter.

New Aker BioMarine Group EVP (10.08.09)

Matts Johansen (32) has been appointed new Group EVP in charge of sales and marketing of the biotechnology company Aker BioMarine. Mr. Johansen will join Aker BioMarine this fall.

Presentation of Q2 2009 results (04.08.09)

Aker BioMarine ASA will release its interim report for the second-quarter on August 11, 2009. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its second-quarter 2009 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Superba Krill Oil better than fish oil (30.06.09)

The nutraceutical Superba Krill Oil, rich in omega-3 phospholipids, gives substantially more reduction of fat in the heart and the liver than omega-3 from fish oil. This is demonstrated in a new preclinical study performed for the biotechnological company Aker BioMarine.

Aker BioMarine strengthens organization (11.06.09)

The biotechnology company Aker BioMarine is strengthening finance, and pharmaceutical-market operations.

Superba — on its way to global markets (05.05.09)

Aker BioMarine’s Superba™ Krill Oil was the best-selling omega-3 product in Norwegian health food stores in the first quarter of 2009, according to statistics from the health food wholesaler Macronova. Now, this unique dietary supplement product is on its way to international markets.

Presentation of Q1 2009 results (28.04.09)

Aker BioMarine ASA will release its interim report for the first-quarter on May 5, 2009. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its first-quarter 2009 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Notification of trade (21.04.09)

Aker Capital AS has renewed a total return swap with 2,500,00 underlying shares in Aker BioMarine ASA. Close is 20 July 2009. Strike NOK 4.8073 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 74,657,494 shares in Aker BioMarine ASA, i.e. 82.9%.

Updated financial calendar for 2009 (16.04.09)

Aker BioMarine have modified the previously announced time and date for publication of first-quarter 2009 report. New date as follows:

5 May 2009 (rescheduled from 29 April)

Annual General Meeting (02.04.09)

Aker BioMarine ASA has today on 2 April 2009 held its Annual General Meeting. All proposals to the AGM were approved.

An Norwegian and English copy of the minutes of the meeting are attached. Please also find the presentation attached.

Nomination Committee Recommendations (27.03.09)

Enclosed please find recommendations from Aker BioMarine ASA’s Nomination committee in connection with the company’s Annual General Meeting on 2 April 2009.

AKBM Recommendations
AKBM CV

Notice of Annual General Meeting (19.03.09)

The shareholders in Aker BioMarine ASA are invited to attend the Annual General Meeting to be held on Thursday 2 April 2009 at 11.00 hrs at Felix Conference Centre, Bryggetorget 3, Aker Brygge, Oslo, Norway.

Preliminary notice of Aker BioMarine ASA annual general meeting (13.03.09)

Please see attached preliminary notice of annual general meeting for Aker BioMarine ASA, attendance ballot and annual report for 2008. The notice of the annual general meeting and attachments will be sent to all shareholders with an known address separately on 19 March 2009.

Annual information 2008 (12.03.09)

Issuers of listed transferable securities are required to provide Oslo Stock Exchange with an annual statement of information made available to the public, cf the Stock Exchange Regulations, section 5-2 fifth paragraph. Attached is an annual overview for Aker BioMarine ASA for the period 12 March 2008 - 11 March 2009.

Superba Krill off to promising start (13.02.09)

The biotechnology company Aker BioMarine is experiencing strong and growing interest in Superba Krill Oil. In January 2009 the dietary supplement was the best-selling omega-3 product in Norwegian health food shops.

Presentation of 4Q 2008 results (06.02.09)

Aker BioMarine ASA will release its interim report for the fourh quarter on February 13, 2009. On the day of the release, representatives of the company will present the results at

Jostein Dalland to leave Aker BioMarine (27.01.09)

The biotechnology company Aker BioMarine has begun the search for a successor to Jostein Dalland, Group EVP, Sales and Marketing. Mr. Dalland has decided to leave Aker BioMarine for personal reasons.

Hallvard Muri new CEO of Aker BioMarine (09.01.09)

Hallvard Muri (48) has been appointed president and chief executive officer of Aker BioMarine ASA. He takes over from Kjell Inge Røkke, who has led the biotechnology company since August 2008.

Aker buys the Antarctic Navigator (22.12.08)

The Board of Aker ASA has approved the agreement from September this year to buy the vessel the Antarctic Navigator. The purchase price is NOK 550 million, as previously communicated.

Completion of acquisition of shares in Aker Ocean Harvest AS (08.12.08)

Reference is made to stock exchange announcement dated 3 December 2008 regarding Aker Seafoods Holding AS’ acquisition of the existing shares in Aker Ocean Harvest AS. Aker Seafoods Holding AS’ acquisition of the existing shares in Aker Ocean Harvest AS has now been completed.

For further information please contact:
EVP & Partner Geir Arne Drangeid, Aker, tel. + 47 24 13 00 65
EVP & CFO Aaron Kramer, Aker BioMarine, tel. + 47 916 30 130

Extraordinary general meeting (04.12.08)

Aker BioMarine ASA has today, on 4 December 2008, held an extraordinary general meeting. All items on the agenda were resolved by the general meeting in accordance with the notice for the meeting, and the agreement regarding the sale of the existing shares of Aker Ocean Harvest AS was approved by the general meeting.

Please find attached minutes from the meeting in Norwegian and English.

For further information please contact:
EVP & Partner Geir Arne Drangeid, Aker, tel. + 47 24 13 00 65
EVP & CFO Aaron Kramer, Aker BioMarine, tel. + 47 916 30 130

Result of offering of shares in Aker Ocean Harvest AS (03.12.08)

Reference is made to previous stock exchange announcements regarding the offering of shares in Aker Ocean Harvest AS.

The offer period for the offering expired at 17:30 hours, CET, on 2 December 2008.

The conditions for completion of the offering have not been met, and the 9,011,212 existing shares in Aker Ocean Harvest AS will thus be acquired by Aker Seafoods Holding AS at NOK 22.58 per existing share pursuant to the terms and conditions of the offering.

Arctic Securities ASA has been the manager for the offering.

For further information please contact:
EVP & Partner Geir Arne Drangeid, Aker, tel. + 47 913 10 458
EVP & CFO Aaron Kramer, Aker BioMarine, tel. + 47 916 30 130

Unique pre-clinical results on Superba™ Krill Oil (19.11.08)

Aker BioMarine has performed four animal studies in mice and rats with SuperbaTM. To investigate the beneficial effects of SuperbaTM three different models has been used for this purpose:
A) High fat fed mice – a diet-induced obesity model – 2 studies
B) Zucker rats – a genetic obesity model – 1 study
C) Effects on collagen-induced arthritis in mice – 1 study

Publication of information memorandum for Aker BioMarine (19.11.08)

Reference is made to previous stock exchange announcements. Please find attached an information memorandum prepared pursuant to section 3.5 of the continuing obligations for companies listed on Oslo Børs and in connection with (i) the offering of shares in Aker Ocean Harvest AS to existing shareholders of Aker BioMarine, and (ii) the sale of the vessel Antarctic Navigator to Aker ASA.

For further information please contact:
EVP & Partner Geir Arne Drangeid, Aker, tel. + 47 913 10 458
EVP & CFO Aaron Kramer, Aker BioMarine, tel. + 47 916 30 130

Offering of shares in Aker Ocean Harvest AS (19.11.08)

Reference is made to previous stock exchange announcements on the planned offering of shares in Aker Ocean Harvest AS. Oslo Børs has approved the prospectus for the offering of shares in Aker Ocean Harvest AS.

AKBM - Extraordinary Shareholders Meeting of Aker BioMarine ASA (13.11.08)

The shareholders in Aker BioMarine ASA are invited to attend the Extraordinary General Meeting to be held on Thursday 4 December 2008 at 10.00 hrs at Felix Conference Centre, Bryggetorget 3, Aker Brygge, Oslo, Norway, in order to consider the approval of the agreement regarding the sale of the shares of Aker Ocean Harvest AS.

Strong foundation for focused development (13.11.08)

Aker BioMarine continues its development through intensified focus on core activities. In the third quarter of 2008, the company implemented an action plan, streamlined the organization to focus on its core expertise in sustainable harvesting of Antarctic krill and the production of high-value bioactive products, and advanced its documentation, sales and marketing efforts.

Information on allocation rights to shares in Aker Ocean Harvest (12.11.08)

The board of directors of Aker BioMarine ASA have today resolved to transfer the fisheries business of the group in Argentine and on the Faroe Islands to Aker Ocean Harvest AS. The shareholders of Aker BioMarine will be offered shares in the newly established company Aker Ocean Harvest AS.

Aker BioMarine sells fisheries operations (12.11.08)

The board of directors of Aker BioMarine ASA has today resolved to transfer the fisheries business of the group in Argentine and on the Faroe Islands to Aker Ocean Harvest AS. The shareholders of Aker BioMarine will be offered shares in the newly established company Aker Ocean Harvest AS.

Presentation of 3Q 2008 results (03.11.08)

Aker BioMarine ASA will release its interim report for the third quarter on November 13, 2008. On the day of the release, representatives of the company will present the results at

Hotel Continental, Bankett & Konferanseavdeling, Stortingsgaten 24/26, Oslo. The presentation begins at 08.30 a.m.

CFO and Executive Vice President Aaron Kramer will give you an updating from the company.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its third-quarter 2008 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Sustainability of operations (27.10.08)

Aker BioMarine has successfully passed a pre-assessment for Marine Stewardship Council (MSC) certification of its sustainable operations. The company will now proceed for full MSC assessment.

Aker BioMarine applies for MSC certification for its Antarctic krill operations (13.10.08)

Aker BioMarine has successfully completed a pre-assessment for Marine Stewardship Council (MSC) accreditation of its Antarctic krill fishing operations. The company will now proceed to a full MSC assessment.

Breakthrough for new production solution (17.09.08)

Aker BioMarine has found a new solution for cost-effective production of a new nutritional health ingredient for human consumption. The breakthrough is presented today at the company’s capital markets day.

Aker BioMarine capital markets day (10.09.08)

Aker BioMarine is holding its capital markets day on Wednesday September 17 at 0930 CET in the Felix conference centre at Aker Brygge in Oslo.

The company’s chairman Leif-Arne Langøy, chief executive Kjell Inge Røkke and other key personnel from Aker BioMarine will be present at the meeting.

Presentations will be given to analysts, investors and other interested parties who register for the event. For practical reasons, we kindly ask all attendees to register participation via e-mail to merete.kildahl@akerbiomarine.com by 1600 CET on Monday September 15.

For further information please contact:
Geir Arne Drangeid, Senior partner and EVP Aker AS, tel. +47 913 10 458
Aaron Kramer, CFO and IR manager, tel. + 47 916 30 130

Sharper focus on krill (04.09.08)

The biotechnology company Aker BioMarine continues to focus on its core business, krill harvesting and processing, and is de-emphasizing activities associated with concentrated fish oils.

Group management changes (27.08.08)

The biotechnology company Aker BioMarine has modified its management team. Aaron Kramer is the company’s new Chief Financial Officer. Prior to appointment as CFO, Mr. Kramer was EVP in charge of business development and strategy.

Helge Midttun leaves Aker BioMarine (20.08.08)

Helge Midttun is stepping down as President and CEO of Aker BioMarine, effective today. Kjell Inge Røkke will for the coming period take charge of leading the company, which is 82.9 per cent owned by Aker.

Notification of trade (19.08.08)

Aker Capital AS has renewed a total return swap with 1,669,906 underlying shares in Aker BioMarine ASA. Close is 20 October 2008. Strike NOK 16.7209 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 74,657,493 shares in Aker BioMarine ASA, i.e. 82.9%.

Meldepliktig Handel (12.08.08)

Helle Kruse Nielsen, styremedlem i Aker BioMarine ASA, kjøpte 11. august 2008, 30.000 aksjer i Aker BioMarine ASA. Aksjene er kjøpt til kurs NOK 16,00. Helle Kruse Nielsen eier etter dette 30.000 aksjer i Aker BioMarine ASA.

Meldepliktig handel (08.08.08)

Nils Brendemo, finansdirektør i Aker BioMarine ASA, har i dag 8. august 2008 kjøpt 3.000 aksjer i Aker BioMarine ASA. Aksjene er kjøpt til kurs NOK 16,00. Nils Brendemo eier etter dette 5.000 aksjer i Aker BioMarine ASA.

Superba™ production scaling up (08.08.08)

The biotechnology company Aker BioMarine is scaling up its industrial production of the high-value krill oil Superba™ as a dietary supplement. Start-up phase challenges in transitioning from small-scale manufacturing to industrial production have been solved.

Presentation of 2Q 2008 results (30.07.08)

Aker BioMarine ASA will release its interim report for the second quarter on Friday 8 August, 2008. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its second-quarter 2008 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Meldepliktig handel (15.07.08)

Hogne Vik, konserndirektør i Aker BioMarine ASA, har gjennom sitt selskap ENG AS 14. juli 2008 kjøpt 4.000 aksjer i Aker BioMarine ASA. Aksjene er kjøpt til kurs NOK 14,50. Eng AS eier etter dette 44.000 aksjer i Aker BioMarine ASA.

Meldepliktig handel (08.07.08)

Hogne Vik, konserndirektør i Aker BioMarine ASA, har gjennom sitt selskap ENG AS kjøpt 10.000 aksjer i Aker BioMarine ASA. Aksjene er kjøpt til kurs NOK 15,-. Eng AS eier etter dette 40.000 aksjer i Aker BioMarine ASA.

Mandatory notification of trade (30.05.08)

Aker Seafoods Holding AS, a wholly owned subsidiary of Aker ASA, has bought 2,233,415 shares in Aker BioMarine ASA at a price of NOK 16.48 per share. New holding is 74,707,494 which represent 82.9 % of the issued share capital. Aker Capital AS, a wholly owned subsidiary of Aker ASA, holds a total return swap with 1, 669,906 underlying shares in Aker BioMarine ASA. Close is 18 August 2008.

Mandatory notification of trade (09.05.08)

Aker Seafoods Holding AS, a wholly owned subsidiary of Aker ASA, has
bought 3,692,241 shares in Aker BioMarine ASA at a price of NOK 16
per share. New holding is 72,474,079 which represent 80.4 % of the
issued share capital. Aker Capital AS, a wholly owned subsidiary of
Aker ASA, holds a total return swap with 1, 669,906 underlying shares
in Aker BioMarine ASA. Close is 18 August 2008.

Great interest in Superba™ in international markets (29.04.08)

In the first quarter of 2008, the biotechnology company Aker BioMarine introduced the high value krill-oil Superba™ in the US. Market reception has been very good.

Secures financing for growth and development (28.04.08)

The biotechnology company Aker BioMarine has secured a NOK 400 million subordinated convertible loan. The loan will provide financial clout for Aker BioMarine’s targeting of international growth markets and the company’s further development.

Presentation of 1Q 2008 results (22.04.08)

Aker BioMarine ASA will release its interim report for the first quarter on Tuesday 29 April, 2008. On the day of the release, representatives of the company will present the results at

Shippingklubben, Haakon VII’s gt. 1, 0112 Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its first-quarter 2008 interim report to the Oslo Stock Exchange prior the the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Avholdt generalforsamling (03.04.08)

Aker BioMarine ASA har i dag 3. april 2008 avholdt ordinær generalforsamling. Bortsett fra agendapunkt 3 ble alle forslag vedtatt i henhold til innkallingen.

Vedlagt oversendes protokoll for generalforsamlingen på norsk og engelsk.

Nomination Committee Recommendations (17.03.08)

Enclosed please find the recommendations of Aker BioMarine ASA‘s Nomination Committee in connection with the company‘s Annual General Meeting on April 3, 2008.

The recommendations include proposals for remuneration of Board and Nomination Committee members.

For further information please contact:
Helge Midttun, CEO, Aker BioMarine, tlf 913 35 790
Nils Brendemo, CFO, Aker BioMarine, tlf 915 48 015

Valgkomitéens innstilling (17.03.08)

Vedlagt følger innstilling fra Aker BioMarine ASAs valgkomité i forbindelse med selskapets ordinære generalforsamling 3. april 2008.

Innstillingen omfatter forslag til honorarer til medlemmene av selskapets styre og valgkomité.

For nærmere informasjon, vennligst kontakt:
Konsernsjef Helge Midttun, Aker BioMarine, tlf 913 35 790
Finansdirektør Nils Brendemo, Aker BioMarine, tlf 915 48 015

Financing of ambitious plans (14.03.08)

The Board of Directors of the biotechnology company Aker BioMarine ASA asks its Annual Shareholders’ Meeting to authorise to obtain a subordinated convertible loan of up to MNOK 700. This will provide financial strength for further development of the company’s plans within international growth markets.
The request for such authorisation will be presented at the Annual Shareholders’ Meeting of Aker BioMarine on April 3, 2008.

Innkalling til ordinær generalforsamling (14.03.08)

Aksjonærene i Aker BioMarine ASA innkalles til ordinær generalforsamling torsdag 3. april 2008 kl. 10.00 på Felix konferansesenter, Bryggetorget 3, Aker Brygge, Oslo.

Notice of Annual General Meeting (14.03.08)

The shareholders in Aker BioMarine ASA are invited to attend the Annual General Meeting to be held on Thursday 3 April 2008 at 10.00 hrs at Felix Conference Centre, Bryggetorget 3, Aker Brygge, Oslo, Norway.

Annual information 2007 (13.03.08)

Issuers of listed transferable securities are required to provide
Oslo Stock Exchange with an annual statement of information made
available to the public, cf the Stock Exchange Regulations, section
5-2 fifth paragraph. Attached is an annual overview for Aker BioMarine ASA for the period 1 January 2007 - 13 March 2008

Ready for launch (15.02.08)

In 2007, the biotechnology company Aker BioMarine achieved important, broad-ranging advances throughout its value chain. Shortly, the company will launch both its dietary supplement Superba™ and Qrill™ krill oil.

Presentation of 4Q 2007 results (04.02.08)

Aker BioMarine ASA will release its interim report for the fourth quarter on Friday 15 February, 2008. On the day of the release, representatives of the company will present the results at Felix konferansesenter, Bryggetorget 3, Aker Brygge, 0250 Oslo. Meetingroom Lancing.
The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its fourth-quarter 2007 interim report to the Oslo Stock Exchange prior the the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Notification of trade (24.01.08)

Aker Capital AS has bought a total return swap with 1,669,906 underlying shares in Aker BioMarine ASA. Close is 18 August 2008. Strike NOK 18.48 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 68,731,837 shares in Aker BioMarine ASA, i.e. 76.3%.

Advances across the value chain (01.11.07)

The biotechnology company Aker BioMarine has developed a new dietary supplement: Superba™. Market launch of Superba™ is scheduled for March 2008. In the third quarter of 2007, Aker BioMarine achieved progress across its value chain.

Aker BioMarine signs krill oil extraction agreements (29.10.07)

The biotechnology company Aker BioMarine has entered into agreements in New Zealand and France that secure production of high-value krill oil.

Aker BioMarine builds Life Science Factory (24.10.07)

The biotechnology company Aker BioMarine is converting the modern trawler Atlantic Navigator into an advanced factory for harvesting and processing health-promoting ingredients from krill.

Aker BioMarine strengthens its organization (15.10.07)

The biotechnology company Aker BioMarine is strengthening its Group management. Hogne Vik has been appointed Group EVP in charge of the Pharma business area. Sjur Tveite has been appointed Group EVP for the Aquaculture & Animal business area. Aaron Kramer is the Group’s new EVP for Strategy & Business Development.

Excellent results for Qrill (30.08.07)

Aker BioMarine’s Qrill™ krill meal demonstrates excellent aquaculture yield improvement. Salmon fed the company’s Qrill™ product weigh 18 and 23 percent more than salmon that consumed fish feed that did not contain Qrill™ — according to studies performed by AKVAFORSK, a leading Norwegian aquaculture research institution.

Aker BioMarine builds brand names (13.08.07)

Aker BioMarine continued to advance its production and sales of krill meal in the second quarter of 2007. The company is building its own brand names.

Aker BioMarine acquires Atlantic Navigator (06.07.07)

Aker BioMarine doubles its in-house production capacity for krill meal through its acquisition of the factory ship Atlantic Navigator.

Implementation of merger between Natural ASA and Aker BioMarine ASA (05.06.07)

On 29 March 2007 the merger between Natural ASA (“Natural”) and Aker BioMarine ASA (“Aker BioMarine”), both subsidiaries of Aker ASA, was approved by shareholders. Following expiry of the creditor notice period on 4 June 2007, the merger is implemented effective from today, 5 June 2007.

Two krill-licenses awarded to Aker BioMarine (31.05.07)

The Norwegian Directorate of Fisheries today announced that Aker BioMarine has been awarded two licenses for krill-fisheries in the Antarctic. The licenses are related to the vessels Saga Sea and Atlantic Navigator. Saga Sea has already been operating on a temporarily license in the Antarctic.

Aker BioMarine ahead of schedule (08.05.07)

Aker BioMarine’s first-quarter 2007 accounts show that the company is ahead of its original schedule for profit performance and efficient production of krill meal.

Bond Issue for Aker BioMarine ASA (07.05.07)

Aker BioMarine ASA to establish NOK 750 million bond loan.

Aker BioMarine ASA (AKBM) has decided to issue its first bond loan. The bond loan will have 3 years maturity with floating interest rate (3 month NIBOR + margin). The borrowing limit will be NOK 1.000 million, while the first tranche will be NOK 750 million.

Aker BioMarine makes decisive market moves (20.03.07)

Aker BioMarine is implementing measures that will enable the company to deliver own volumes of krill oil produced on board the company’s modern factory trawlers, as early as in 2009. The company is also strengthening its financial clout.

Financial statement (02.03.07)

Please find attached the Aker BioMarine’s financial statement. Profit and loss for 2006 and 2005 and the lance sheet at 31.12 are pro forma, as the Aker BioMarine Group (Natural owned 89.14 %) was formed 1 January 2005.
As announced 27 February, Aker BioMarine’s 2006 profit performance accords with the company’s business plan.

Aker BioMarine 4th quarter 2006 (01.03.07)

Please find attached the presentation material used at today‘s presentation of Aker BioMarine‘s fourth quarter results 2006.

Aker BioMarine and Natural agree to merge (27.02.07)

The boards of directors of Aker BioMarine and the biotechnology company Natural have agreed to recommend a merger of the two companies. The merged company will be called Aker BioMarine. The company will become a leader in the production of valuable, bioactive marine additives and ingredients for the food, dietary supplements, pharmaceuticals, and aquaculture industries.

Aker BioMarine on schedule (27.02.07)

Aker BioMarine’s 2006 profit performance accords with the company’s business plan. Aker BioMarine had 2006 operating revenues of NOK 460 million; operating profit before depreciation and amortization (EBITDA) amounted to NOK 26 million, according to pro forma accounts for 2006 as a whole.

Presentation of 4th quarter results for 2006 (22.02.07)

Aker ASA, Aker American Shipping ASA, Aker Floating Production ASA, Aker Drilling ASA, Aker BioMarine ASA and Aker Exploration ASA release their preliminary annual and 4th quarter results for 2006 on Thursday 1 March 20007.

Aker BioMarine ASA – Pro Forma Financial Information (11.12.06)

The following sets forth pro forma consolidated financial information for the year ended 31 December 2005 and for the three first quarters of 2006. The pro forma combined financial information has been derived from financial information in the consolidated accounts of Aker ASA and financial information from Natural ASA and Krill A/S.

Gain on the establishment of Aker BioMarine (08.12.06)

The establishment of Aker BioMarine and that company’s recently completed share issue have resulted in an approximately NOK 3.5 billion positive profit effect for Aker in the fourth quarter of 2006. The gain will be reported in Aker ASA’s accounts (parent and holding company).

Aker BioMarine – completed private placement (08.12.06)

Aker BioMarine, a subsidiary of Aker, has completed the previously announced private placement and has raised NOK 1.2 billion in new funding from Norwegian and international investors. The price per share was set at NOK 90, valuing the company at NOK 5,070 million after the placement, divided into 56 333 300 shares. Aker’s ownership following the private placement is 76.2 %.

Helge Midttun appointed as President and CEO of Aker Biomarine (26.09.06)

Aker has appointed Helge Midttun as President and CEO of its Aker BioMarine subsidiary. Aker BioMarine specializes in harvesting and processing of fish and krill into valuable products for the aquaculture and food industries, and other industrial applications.

Superba Krill
Norsk forbrukerkontakt:
Telefon: 815 56 333
Send epost

For international
Superba Krill enquiries:

For Europe:
Phone: +47 24 13 00 00
Send email
For North America:
Phone: 1-206-855-6736
Send email